ImClone Opts Out Of Anti-VEGF Deal With UCB To Focus On Proprietary Compound
This article was originally published in The Pink Sheet Daily
Executive Summary
ImClone will develop IMC-1121B after the biologic demonstrated promising clinical activity in Phase I, firm says.